Advancing Integrity and Ethics in Montana Healthcare

RESOURCE LIBRARY

RESOURCES

Resources are provided for educational purposes and may include primary research, government documents, professional statements, legal opinions, and other materials representing differing types and levels of evidence. Inclusion does not necessarily constitute endorsement of every conclusion or interpretation contained in a source. Readers are encouraged to review original materials, consider study design and limitations, and discuss individual medical decisions with a qualified healthcare professional. This resource guide does not provide medical or legal advice.

Use the Type and Topic filters on their own or together. Click a selected filter again, or choose All, to clear it.

Type

Topic

Psychiatric Morbidity Among Adolescents and Young Adults Who Contacted Specialised Gender Identity Services in Finland in 1996-2019: A Register Study

Sami-Matti Ruuska, Katinka Tuisku, Timo Holttinen, Riittakerttu Kaltiala

Acta Paediatrica

Published April 4, 2026

DOI: 10.1111/apa.70533

2,083 individuals referred to specialized gender identity services before age 23 and 16,643 matched population controls in Finland

This nationwide Finnish register study examined severe psychiatric morbidity among adolescents and young adults referred to specialized gender identity services between 1996 and 2019. Compared with matched population controls, gender-referred individuals had higher rates of specialist-level psychiatric treatment before referral and during follow-up. Psychiatric morbidity was greater among individuals referred after 2010 than among earlier cohorts. Among those who underwent medical gender reassignment, psychiatric morbidity increased during follow-up; after adjustment for prior psychiatric treatment, elevated psychiatric morbidity remained across the gender-referred groups. The authors concluded that psychiatric needs did not subside following medical gender reassignment.

Pediatric Gender Medicine | Gender Dysphoria | Psychiatric Morbidity | Mental Health | Gender Reassignment

Reanalysis of FDA Clinical Data for mFLUSIVA (mRNA-1010): Unfavorable Risk-Benefit Profile Supports Market Withdrawal

Secondary Data Reanalysis

Nicolas Hulscher, Peter A. McCullough, John A. Catanzaro

Zenodo

Published August 19, 2026

DOI: 10.5281/zenodo.22016811

This preprint reanalyzes efficacy and safety data used in FDA review of Moderna’s mRNA-1010 influenza vaccine. The authors calculate absolute risk differences, numbers needed to vaccinate, numbers needed to harm, risk ratios, and related measures and conclude that the product’s benefit-risk profile does not support continued licensure.

mRNA Influenza Vaccine | mFLUSIVA | Vaccine Safety | Risk-Benefit Analysis | FDA

Calls for Market Removal of COVID-19 Vaccines Intensify as Risks Far Outweigh Theoretical Benefits

Narrative Review and Policy Analysis

Nicolas Hulscher, Mary T. Bowden, Peter A. McCullough

Science, Public Health Policy and the Law

Published January 28, 2025

This review compiles published studies, pharmacovigilance data, excess-mortality analyses, vaccine-effectiveness findings, residual-DNA reports, and public calls for suspension or withdrawal of COVID-19 vaccines. The authors argue for market removal and discuss limitations affecting portions of the evidence reviewed, including observational designs, confounding, reporting bias, and the inability of correlations alone to establish causation.

COVID-19 Vaccines | Vaccine Safety | Pharmacovigilance | Excess Mortality | Regulatory Policy

Booster Vaccination with SARS-CoV-2 mRNA Vaccines and Myocarditis in Adolescents and Young Adults: A Nordic Cohort Study

Hviid A, Nieminen TA, Pihlström N, et al.

European Heart Journal

Published 2024

A Nordic cohort study evaluating myocarditis following mRNA COVID-19 booster vaccination among adolescents and young adults. The authors reported increased myocarditis incidence after booster vaccination in younger males while noting that the absolute number of events was low.

COVID-19 Vaccines | Booster Doses | Myocarditis | Adolescents | Young Adults

SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents

Karlstad Ø, Hovi P, Husby A, et al.

JAMA Cardiology

Published 2022

A population-based study using nationwide registry data from Denmark, Finland, Norway, and Sweden to evaluate myocarditis and pericarditis following SARS-CoV-2 vaccination. The study reported increased myocarditis risk after mRNA vaccination, with risk varying by age, sex, dose, and vaccine product.

COVID-19 Vaccines | Myocarditis | Pericarditis | mRNA Vaccines | Young Males

FDA COVID-19 Vaccine Regulatory Review Documents

Regulatory Evidence Review

U.S. Food and Drug Administration

FDA regulatory materials include authorization and approval documents, briefing materials, decision memoranda, fact sheets, and advisory-committee materials used in evaluating COVID-19 vaccines. These documents provide primary-source information about regulatory review of efficacy, safety, manufacturing, and benefit-risk considerations.

COVID-19 Vaccines | Pfizer-BioNTech | Moderna | Safety | Efficacy | Regulatory Review

Vaccine Adverse Event Reporting System (VAERS)

Centers for Disease Control and Prevention and U.S. Food and Drug Administration

A national early-warning system that accepts reports of health events occurring after vaccination. Reports can identify potential safety signals for further investigation, but a VAERS report alone does not establish that a vaccine caused the reported event.

Vaccine Safety | Adverse Event Reporting | Pharmacovigilance

Vaccine Safety Datalink (VSD)

Centers for Disease Control and Prevention and participating healthcare organizations

A collaborative vaccine-safety surveillance and research system that uses electronic health-record data from participating healthcare organizations to monitor vaccine safety, investigate potential adverse events, and conduct population-based safety studies.

Vaccine Safety | Adverse Events | Signal Detection | Post-Licensure Surveillance

Christian Medical & Dental Associations

CMDA

A professional association for Christian healthcare professionals that publishes ethics statements on the moral worth of human life, abortion, beginning-of-life questions, disability, suicide, end-of-life care, human research, and related medical-ethics issues.

Sanctity of Life | Beginning of Life | End-of-Life Ethics | Medical Ethics

American Association of Pro-Life Obstetricians and Gynecologists (AAPLOG)

AAPLOG

A professional association of physicians and other medical professionals that publishes educational materials, practice guidance, committee opinions, and policy statements from a pro-life medical perspective.

Prenatal Human Life | Abortion | Maternal Health | Medical Ethics

Declaration of Helsinki

World Medical Association

An international statement of ethical principles for medical research involving human participants, including requirements related to research protocols, informed consent, vulnerable populations, risk-benefit assessment, and scientific integrity.

Human Research | Medical Ethics | Informed Consent

The Belmont Report

U.S. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research

Published 1979

A foundational U.S. research-ethics document identifying three core principles for research involving human subjects: respect for persons, beneficence, and justice. It also discusses informed consent, assessment of risks and benefits, and selection of research subjects.

Research Ethics | Informed Consent | Human Subjects